Screening for Hepatocellular Carcinoma in Patients with Cirrhosis

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period.

Date Reviewed: November 19, 2017

Measure Info

MIPS 401 CMS 401
Measure Type
Measure Steward
American Gastroenterological Association
Clinical Topic Area
Hepatitis C

Care Setting
Data Source

ACP does not support QPP measure 401: "Hepatitis C: Screening for Hepatocellular Carcinoma" because the screening benefits do not outweigh the substantial risks of harms related to radiation exposure and treatment of incidental findings. Furthermore, developers cite weak evidence to form the basis of the measure. A recent evidence review demonstrates insufficient evidence for screening for hepatocellular carcinoma among patients with cirrhosis.